Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - Results from a randomized-controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 11-12, 2004, Pages 1353-1363

  Raedler, A ^a   Behrens, C ^b   Bias, P ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MESALAZINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG MICROPELLET; DRUG PELLET; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TABLET FORMULATION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; HUMANS; MESALAMINE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; TABLETS; TREATMENT OUTCOME;

EID: 11144297984     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02282.x     Document Type: Article

References (46)

1. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 331-40.
2. Gionchetti P, Rizzello F, Habal F, et al. Standard treatment of ulcerative colitis. Dig Dis 2003: 21: 157-67.
3. Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 410-4.
4. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 2000; 14: 163-9.
5. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
6. Egan LJ, Sandborn WJ. Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 1998; 34: 431-46.
7. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333-6.
8. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83.
9. Kane S. Patient compliance and outcomes. Inflamm Bowel Dis 1999; 5: 134-7.
10. Moum B, Medical treatment: does it influence the natural course of inflammatory bowel disease? Eur J Intern Med 2000; 11: 197-203.
11. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
12. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43.
13. Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 2001; 49: 783-9.
14. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002(4): CD000544. Review.
15. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003(3): CD000543. Review.
16. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review. Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004; 19: 179-89.
17. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33.
18. Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterology 1988; 94: 1089-91.
19. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53.
20. Allgayer H. Review article: Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18 (Suppl. 2): 10-4.
21. Reinacher-Schick A, Seidensticker F, Petrasch S. et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000; 32: 245-54.
22. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
24. AWMF-Leitlinien-Register Nr. 021/009. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, 2000. Accessed at http://www. uni-duesseldorf.de/AWMF/ll/iverd009.htm.
25. Schölmerich J, Stange EF. Chronic inflammatory bowel diseases: drug therapy standards and trends. Internist (Berl) 2001; 42: 533-8, 540-3.
26. Herrlinger K, Fellermann K, Stange EF. Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations. Internist (Berl) 2002; 43: 1367-8, 1371-5.
27. Wilding IR, Behrens C, Tardif SJ, Wray H, Bias P, Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther 2003; 17: 1153-62.
28. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
29. Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99: 457-61.
30. Lorenz R, Olbert P, Born P. Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost 1996; 22: 451-5.
31. FDA. Points to consider. Division of anti-infective drug products. Clinical Development and Labelling of Anti-infective Drug Products, 1995. Report No. 2: p.20.
32. Kruis W, Brandes JW, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 707-15.
33. Farup PG. Compliance with anti-ulcer medication during short-term healing phase clinical trials. Aliment Pharmacol Ther 1992; 6: 179-86.
34. Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 1983; 25: 63-76.
35. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
36. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104: 1293-301.
37. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7.
38. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4.
39. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001; 7: 237-42.
40. Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002; 16: 1889-93.
41. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-92.
42. Courtney ED, Melville DM, Leicester RJ. Review article: Chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2004; 19: 1-24.
43. Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 2003; 18: 392-100.
44. Ryan BM, Russel MG, Langholz E, Stockbrugger RW. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 2003; 98: 1682-7.
45. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003; 17: 517-23.
46. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.